CN Patent

CN107921037A — 含pi3k抑制剂alpelisib和b‑raf抑制剂达拉菲尼的药物组合；该组合在治疗或预防癌症中的应用

Assigned to Novartis AG · Expires 2018-04-17 · 8y expired

What this patent protects

本公开涉及药物组合，包括(a)α‑同种型特异性PI3K抑制剂和(b)B‑RAF抑制剂；其联合制剂和药物组合物；该组合在治疗或预防癌症中的应用；以及在对象中治疗或预防癌症的方法，包括施用治疗有效量的该组合。

USPTO Abstract

本公开涉及药物组合，包括(a)α‑同种型特异性PI3K抑制剂和(b)B‑RAF抑制剂；其联合制剂和药物组合物；该组合在治疗或预防癌症中的应用；以及在对象中治疗或预防癌症的方法，包括施用治疗有效量的该组合。

Drugs covered by this patent

ribociclib-succinate (RIBOCICLIB SUCCINATE)

Patent Metadata

Patent number: CN107921037A
Jurisdiction: CN
Classification: —
Expires: 2018-04-17
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.